Back to News
Market Impact: 0.15
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Nautilus Biotechnology reported $0.2 million in revenue for the third quarter ended September 30, 2026, primarily from grant revenue tied to its activities under a grant awarded by The Michael. The available article text provides no comparison, outlook, or other financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios